AnaptysBio Inc
NASDAQ:ANAB
AnaptysBio Inc
Revenue
AnaptysBio Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
AnaptysBio Inc
NASDAQ:ANAB
|
Revenue
$17.2m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
See Also
What is AnaptysBio Inc's Revenue?
Revenue
17.2m
USD
Based on the financial report for Dec 31, 2023, AnaptysBio Inc's Revenue amounts to 17.2m USD.
What is AnaptysBio Inc's Revenue growth rate?
Revenue CAGR 5Y
28%
Over the last year, the Revenue growth was 67%. The average annual Revenue growth rates for AnaptysBio Inc have been -39% over the past three years , 28% over the past five years .